Besides counteracting obesity, perhaps activating the H1 receptor by using betahistine, or another H1 receptor agonist, could also inhibit NLRP3/caspase-1 signaling and thus pyroptosis and brain volume loss induced by chronic antipsychotic treatment. The gene discussed is CASP1; the disease is obesity due to melanocortin 4 receptor deficiency.